gene editing

News

Metagenomi prices IPO and NeOnc joins list of hopefuls

Gene editing start-up Metagenomi and cancer specialist NeOnc Technologies have announced the terms of their initial public offerings, in another sign that investor interes

News

Intellia’s president and chief executive John Leonard

Intellia’s CRISPR drug could offer one-shot HAE treatment

A single dose of a gene-editing drug being developed by Intellia Therapeutics almost eliminated attacks in patients with hereditary angioedema (HAE) in a clinical trial, p

News

A giemsa stained blood smear from a person with beta thalassaemia

First CRISPR drug Casgevy gets swift second approval

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-

R&D

JP Morgan 2024 – Jeff Smith

Editor-in-chief Jonah Comstock sat down with Jeff Smith, chief research officer at Precision BioSciences, on the side lines of the JP Morgan Healthcare Conference in San Francisco to discus

R&D

5 changes underway for R&D IT shifting to advanced modalitie...

Back in 2000, the FDA approved only six biologics versus 27 new molecular entities (NMEs).

News

Sangamo sheds staff once again in another retreat

Sangamo Therapeutics has announced another wave of job losses and a plan to license out two lead clinical programmes as it tries to reinvent itself as a neurology-focused

Metagenomi prices IPO and NeOnc joins list of hopefuls

Intellia’s CRISPR drug could offer one-shot HAE treatment

First CRISPR drug Casgevy gets swift second approval

JP Morgan 2024 – Jeff Smith

5 changes underway for R&D IT shifting to advanced modalitie...

Sangamo sheds staff once again in another retreat

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

gene editing

Editor's Picks